Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 130

Results For "C"

9138 News Found

UFlex introduces FSSAI compliant single-pellet solution for food packaging
Packaging | June 20, 2025

UFlex introduces FSSAI compliant single-pellet solution for food packaging

UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials


Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
News | June 17, 2025

Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China

SUP will obtain regulatory approvals for selling Tiotropium DPI in China


USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
Drug Approval | June 17, 2025

USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

The company received one observation in the Form-483


USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru
Drug Approval | June 17, 2025

USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru

The inspection concluded successfully, with the facility found to be in compliance with the required regulations


Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
News | June 16, 2025

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies


AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
News | June 16, 2025

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing


Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
News | June 16, 2025

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression


Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
News | June 16, 2025

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities


NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery
Digitisation | June 13, 2025

NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery

The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development